Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
0.8645
+0.0105 (1.23%)
At close: May 15, 2025, 4:00 PM
0.8588
-0.0057 (-0.66%)
After-hours: May 15, 2025, 7:32 PM EDT
Clearside Biomedical Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Clearside Biomedical stock ranges from a low of $3.00 to a high of $6.00. The average analyst price target of $5.00 forecasts a 478.37% increase in the stock price over the next year.
Price Target: $5.00 (+478.37%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Clearside Biomedical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | +247.02% | May 15, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +362.70% | Apr 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +594.04% | Mar 31, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $5 | Buy | Reiterates | $5 | +478.37% | Mar 28, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +594.04% | Mar 28, 2025 |
Financial Forecast
Revenue This Year
839.32K
from 1.66M
Decreased by -49.56%
Revenue Next Year
6.51M
from 839.32K
Increased by 675.15%
EPS This Year
-0.44
from -0.47
EPS Next Year
-0.66
from -0.44
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.7M | 21.3M | 49.7M | ||
| Avg | 839,317 | 6.5M | 20.6M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.0% | 2,438.4% | 663.9% | ||
| Avg | -49.6% | 675.2% | 216.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.25 | -0.26 | -0.29 | ||
| Avg | -0.44 | -0.66 | -0.47 | ||
| Low | -0.61 | -1.20 | -0.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.